Home Latest News ICMR Spearheads Development of Indigenous Multi‑Stage Malaria Vaccine ‘AdFalciVax’: Efficacy, Timeline And Key Facts
Latest News

ICMR Spearheads Development of Indigenous Multi‑Stage Malaria Vaccine ‘AdFalciVax’: Efficacy, Timeline And Key Facts

Share
Share

New Delhi, 21 July 2025: India’s premier research body has launched a major initiative to develop AdFalciVax, an indigenous multi‑stage malaria vaccine, as part of its malaria elimination strategy. The vaccine is being created by a consortium led by a regional research centre, with support from national immunology and malaria research institutes. Designed as a recombinant chimeric vaccine, it targets two critical stages of the Plasmodium falciparum parasite—aiming to both prevent human infection and reduce community transmission.

What Makes AdFalciVax Unique
Unlike existing malaria vaccines that target a single parasite stage, this vaccine is engineered to attack both the pre‑erythrocytic (infection) and sexual (transmission) phases. Its antigen components are produced using Lactococcus lactis, a safe food‑grade bacterium, enabling dual protective mechanisms. Preclinical trials have shown excellent efficacy, reduced risk of immune evasion, potential for stronger long‑term immunity, and thermal stability at room temperature for more than nine months—a major logistic advantage in tropical and remote areas.

Preclinical Results and Potential Benefits
In early lab testing, the vaccine demonstrated broader protection compared to existing formulations like RTS,S/AS01 (Mosquirix) and R21/Matrix‑M. Strengthened antibody responses, lower risk of parasite escape, and sustained activity post-boost in animals suggest the possibility of enhanced long-term immunity. Its extended shelf-life under standard conditions reduces dependency on cold-chain infrastructure, making it ideal for widespread use in low-resource communities.

Development Timeline & Licensing Plan
The technology is still in the preclinical stage; human trials—including Phase I—are expected to begin within the next two years. The complete development, including clinical testing and regulatory clearance, is projected to take approximately seven years across four structured phases, with six-month buffers built into each stage.

The research body has issued an Expression of Interest (EoI) inviting Indian companies and vaccine manufacturers to participate in non-exclusive technology transfer agreements. Selected organizations will be licensed to refine, manufacture, market, and distribute the vaccine, while research institutes will continue to provide technical support and expertise throughout the development and production process. Royalty terms and intellectual property provisions are defined under the institutional policy.

Strategic and Public Health Implications
If successful, AdFalciVax could become one of the world’s most advanced malaria vaccine candidates, aligning with national priorities like the “Make in India” initiative and malaria elimination targets by 2030. It aims to complement existing vaccine options—such as Mosquirix and R21/Matrix–M—for children in high-burden settings. Its dual-stage targeting and easier storage could also make it more effective and accessible across regions that struggle with cold-chain logistics.

Summary Table: AdFalciVax at a Glance

FeatureCurrent Info
TypeIndigenous recombinant chimeric malaria vaccine (dual‑stage)
Target ParasitePlasmodium falciparum
Development PartnersRegional Medical Research Centre, Malaria Research Institute, National Institute of Immunology
Key AdvantagesBroader protection, risk reduction of immune evasion, long-term immunity, heat stability
StorageStable at room temperature ≥ 9 months
Development Timeline~7 years (preclinical to commercialization)
Licensing ModelNon‑exclusive tech transfer to multiple manufacturers
Support MechanismTechnical guidance from research institutes
Public Health RoleComplements existing WHO-backed vaccines; aids elimination efforts

According to the researchers, AdFalciVax has the potential to revolutionize India’s approach to malaria prevention, with broad implications for global public health. It reflects the country’s growing leadership in vaccine innovation and its commitment to equitable access in malaria-endemic settings. ICMR’s focus now shifts to securing collaborations, initiating human trials, and scaling production under robust regulatory and IP frameworks.

Share
Written by
kirti Shah

Kirti is a Health Editor at Healthwire Media, specializing in health journalism and digital health communication. With over four years of experience in the healthcare media landscape, she is dedicated to transforming complex clinical data into accessible, patient-friendly information. Kirti oversees the editorial lifecycle of every article, ensuring they meet rigorous fact-checking standards and align with the latest guidelines from primary sources like the WHO and Ministry of Health. In her role, Kirti works closely with a panel of board-certified physicians and medical reviewers to ensure that every piece of content published is not only easy to understand but also medically accurate and safe for the public. She is passionate about health literacy and helping readers navigate their wellness journeys with confidence.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Don't Miss

Bundibugyo Ebola virus
International NewsVirus & DiseaseWHO

From Fever To Organ Failure: How The Bundibugyo Ebola Virus Affects The Body

The Bundibugyo Ebola virus outbreak has raised fresh global health concerns as infections continue to spread across parts of Central and East Africa....

WHO
Health TipsInternational NewsLatest NewsLifestyle & WellnessWHO

WHO Issues First Type 1 Diabetes Guidelines for Adults: 7 Things Patients Need to Know

More than 100 years after the discovery of insulin, millions of people living with type 1 diabetes continue to face challenges in accessing...

Breast Cancer
Health NewsOncology

Mammogram vs Ultrasound vs MRI: Which Breast Cancer Screening Test Is Right for You?

Breast cancer is one of the most common cancers affecting women worldwide, and early detection plays an important role in improving treatment outcomes....

Always Tired? It Could Be Anaemia!
Diet & NutritionHealth NewsHealth TipsLifestyleLifestyle & WellnessWellness

Anaemia in India: Why Iron Deficiency Remains a Concern and 7 Signs You Should Not Ignore

Feeling tired all the time, experiencing frequent dizziness or getting breathless after climbing a few stairs? While these symptoms are often dismissed as...

N95 Mask
Health TipsLatest NewsLifestyle & WellnessWellness

Does Wearing an N95 Mask Protect You From PM2.5 Pollution? Doctors Explain How To Choose And Wear It Correctly

As air pollution continues to affect several Indian cities during winter, wearing a mask has become an important precaution for people stepping outdoors....

Section title

Related Articles
Latest NewsWHO

WHO Releases First-Ever Guidelines For Type 1 Diabetes In Adults: 5 Key Recommendations Explained

The World Health Organization (WHO) has issued its first-ever guidelines for the...

Health NewsLatest NewsLifestyle

7 Simple Ways to Protect Yourself from Air Pollution

Air pollution has become a major health concern today. Dust from construction...